Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2SCLC, Extensive Stage 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1

Interventions

Injections 7pembrolizumab 5Paclitaxel 5Bevacizumab 5Leucovorin 4Fluorouracil 4Carboplatin 4trifluridine tipiracil drug combination 3Pemetrexed 3Oxaliplatin 3Irinotecan 3Docetaxel 3Capecitabine 3toripalimab 2tislelizumab 2fludarabine 2Nivolumab 2Gemcitabine 2Fulvestrant 2Cisplatin 2BMS-753493 2130-nm albumin-bound paclitaxel 2urelumab 1ulixertinib 1palbociclib 1mogamulizumab 1lenvatinib 1fluzoparib 1duvelisib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumors × fluzoparib × Clear all
NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Risen (Suzhou) Pharma Tech Co., Ltd.

Phase 1/2 Recruiting
306 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡